Rokuronijev bromid B. Braun 10 mg/ml raztopina za injiciranje/infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

rokuronijev bromid b. braun 10 mg/ml raztopina za injiciranje/infundiranje

rokuronijev bromid - raztopina za injiciranje/infundiranje - rokuronijev bromid 10 mg / 1 ml - rokuronijev bromid

Rokuronijev bromid Kabi 10 mg/ml raztopina za injiciranje/infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

rokuronijev bromid kabi 10 mg/ml raztopina za injiciranje/infundiranje

rokuronijev bromid - raztopina za injiciranje/infundiranje - rokuronijev bromid 10 mg / 1 ml - rokuronijev bromid

Sugammadex Mylan Evropska unija - slovenščina - EMA (European Medicines Agency)

sugammadex mylan

mylan ireland limited - sugammadex sodium - neuromuskularna blokada - vsi drugi terapevtski izdelki - reversal of neuromuscular blockade induced by   rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Sugammadex Fresenius Kabi Evropska unija - slovenščina - EMA (European Medicines Agency)

sugammadex fresenius kabi

fresenius kabi deutschland gmbh - sugammadex sodium - neuromuskularna blokada - vsi drugi terapevtski izdelki - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Sugammadex Amomed Evropska unija - slovenščina - EMA (European Medicines Agency)

sugammadex amomed

aop orphan pharmaceuticals gmbh - sugammadex sodium - neuromuskularna blokada - vsi drugi terapevtski izdelki - zavrnitev nevromuskularne blokade, ki jo inducira rocuronium ali vecuronium. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.